Navigation Links
AcelRx Pharmaceuticals Doses the First Patients in ARX-04 Phase 2 Clinical Study
Date:11/5/2012

REDWOOD CITY, Calif., Nov. 5, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.  This study will enroll approximately 100 patients following bunionectomy surgery, randomized into one of three groups; 20 mcg sufentanil NanoTab, 30 mcg sufentanil NanoTab or placebo, administered by healthcare personnel, as needed every hour.  The study will evaluate the ability of sufentanil NanoTabs to manage moderate-to-severe acute pain over the first 12 hours following bunionectomy, and correlate the pain response with sufentanil pharmacokinetics.  AcelRx is conducting the study with funding provided by a grant from the U.S. Army Medical Research and Materiel Command, or USAMRMC.

"ARX-04, a single-dose applicator containing a single sufentanil NanoTab, represents a promising new application of our proprietary NanoTab® technology for sublingual delivery of sufentanil by healthcare personnel, and has the potential to safely provide rapid onset of analgesia for patients in acute pain, both on the battlefield and in civilian settings of trauma or injury," stated Richard King, AcelRx's president and CEO.  

In May 2011, USAMRMC awarded AcelRx a $5.6 million grant to support the development of ARX-04, a proprietary non-invasive, fast-onset sublingual product candidate for the treatment of moderate-to-severe acute pain.  In accordance with the development plans of the grant, AcelRx filed the IND with the FDA during October 2011 and on November 1, 2012 initiated the Phase 2 study following protocol approval by the USAMRMC.
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
11. AcelRx Pharmaceuticals to Present at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  Depomed, Inc. (NASDAQ: ... second quarter fiscal year 2014 financial results after the ... host a conference call beginning at 4:30 pm EDT, 1:30 ... access the call by dialing 877-317-6789 ( United ... will also be available via a live webcast on ...
(Date:7/25/2014)... LAS VEGAS , July 25, 2014 GrowBLOX ... of a binding Memorandum of Understanding ("MOU") with LaurelCo, LLC, ... to pursue the acquisition of both cultivation and dispensary medical ... . Pursuant to the MOU, GBLX will acquire a 20% ... use our proprietary GrowBLOX TM growing chambers, as well ...
(Date:7/25/2014)... ALBANY, New York , July 25, 2014 /PRNewswire/ ... published by Transparency Market Research "Global and China Insulin ... Insulin) - Industry Analysis, Size, Share, Growth, Trends and ... insulin market was valued at USD 19.99 billion in ... of 6.1% from 2013 to 2019 to reach USD ...
Breaking Medicine Technology:Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
... CVS Caremark Corporation (NYSE: CVS ) today announced that Tom Ryan , Chairman, President and CEO, ... to investors at the Barclays Capital 2010 Global Healthcare Conference on March 23, 2010 . The Company is ... ... , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first in class collagenase-based products, today announced its financial results for the fourth quarter and full year ended ... ... ... ...
Cached Medicine Technology:CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 2CVS Caremark to Present at the Barclays Capital 2010 Global Healthcare Conference 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 6BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 7BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 8BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 9BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 10BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 11BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 12BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2009 Financial Results 13
(Date:7/25/2014)... Ticket Down is a reliable source for cheap ... at California Memorial Stadium. With the post-World Cup emotions still ... of the 2014 Guinness International Champions Cup have brought eight ... teams representing La Liga, English Premier League, Serie A, and ... football players from around the world to 12 American cities ...
(Date:7/25/2014)... 2014 On July 22, 2014, ... client and the nation’s number one provider of ... announced their partnership with TransAct Merchant Solutions’ National ... ISO/MSP of Chase Paymentech Solutions, LLC, which provides ... Companies that are members of TransAct’s National Association ...
(Date:7/25/2014)... Hastings and Hastings, a personal ... regard to personal injury claims, announces free initial consultations. ... legal services for those that have been injured as ... corporation. Free initial consultation services gives clients’ greater flexibility ... potential personal injury claim . It also offers clients ...
(Date:7/25/2014)... News) -- Shift workers, especially men, may be at higher ... such schedules, a new study suggests. Also at special ... schedule, with shifts moving around at various times of the ... one expert, Dr. Alan Manevitz, a clinical psychiatrist at Lenox ... known that working shifts disrupts many key body chemicals, creating ...
(Date:7/25/2014)... An experimental anti-inflammatory drug can protect vulnerable neurons ... of Parkinson,s disease, researchers at Emory University School ... published in the Journal of Parkinson,s Disease ... called XPro1595, can reach the brain at sufficient ... subcutaneous injection, like an insulin shot. Previous studies ...
Breaking Medicine News(10 mins):Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 2Health News:Real Madrid vs. Inter Milan Tickets Berkeley: Ticket Down Slashes Ticket Prices on Guinness International Champions Cup Tickets at California Memorial Stadium 3Health News:Nuanced Media Client, CEDR HR Solutions, Partners with TransAct to Serve Medical, Dental, and Eye Care Professionals 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 2Health News:Hastings and Hastings Announces Complimentary Consultation Services 3Health News:Study Links Shift Work to Risk for Type 2 Diabetes 2Health News:Study Links Shift Work to Risk for Type 2 Diabetes 3Health News:Anti-inflammatory drug can prevent neuron loss in Parkinson's model 2
... Case Medical Center and Case Western Reserve University School ... beneficial for women in their 40s. According to a ... Journal of Roentgenology , women between ages 40 and ... earlier stages with smaller tumors than symptomatic women needing ...
... and the scientific community should work to ensure that ... supplements and cancer risk, according to a commentary published ... Cancer Institute . Evidence from animal, in vitro ... may lower cancer risk. However, the small number of ...
... care collaboration to diagnosis, treat and follow patients ... require rapid, resource-intensive care and confer a high ... 24 in Circulation . Specifically, cardiovascular emergencies, ... angina, out-of-hospital cardiac arrest (OHCA), acute aortic dissection ...
... make the difference between life and death for very low ... of Pennsylvania School of Nursing and released today in ... . In a comprehensive study of 72,235 infants born ... babies cared for in hospitals with the Magnet credential were ...
... -- For people with tinnitus, which features chronic ringing, ... poor sleep makes it even more difficult to cope ... study included 117 tinnitus patients treated at Henry Ford ... severe the patients, insomnia, the greater their complaints about ...
... feel too attached? Does one need to let go to mature? ... immature cells, neural stem cells must stick together in a protected ... make all of the cells that populate the nervous system. But ... must stop dividing, detach from their neighbors and migrate to where ...
Cached Medicine News:Health News:Study finds mammography beneficial for younger women 2Health News:Supplements and cancer prevention: A cautionary tale 2Health News:Is it time for regional cardiovascular emergency care systems across the US? 2Health News:Choosing the right hospital may save your baby's life 2Health News:Poor Sleep Heightens 'Ringing Ear' Disease Symptoms: Study 2Health News:Growing up as a neural stem cell: The importance of clinging together and then letting go 2Health News:Growing up as a neural stem cell: The importance of clinging together and then letting go 3
Stainless steel dull finish....
9 mm diameter pigtail curved blunt probes. Stainless steel. Round knurled handle with polished finish. Includes pre-cut polyethylene tubes. Overall length: 5.9 inches....
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The Novus 2000 argon laser combines power, size, and versatility. Ideal for the office, clinic and operating room environments, Novus 2000 is the world's most widely accepted ophthalmic laser....
Medicine Products: